Hemp THC Ban Proceeds as Congress Strips Delay from Spending Bill

Congressional leaders removed provisions that would have delayed a hemp-derived THC ban from the federal spending bill released Tuesday, creating immediate uncertainty for CBD manufacturers and patients awaiting promised Medicaid coverage.

The eliminated language would have postponed enforcement of regulations targeting intoxicating hemp products containing THC—including delta-8 and delta-9 THC derived from hemp. Without the delay, existing federal restrictions on these products remain in effect, potentially complicating President Trump's recent pledge to expand Medicaid coverage for CBD treatments.

The development marks a significant shift in congressional approach to hemp regulation. Earlier versions of the spending legislation included temporary protections sought by hemp industry advocates, who argued that manufacturers needed time to reformulate products and adjust to evolving regulatory standards.

The Policy Collision

The timing creates a regulatory paradox. Trump announced plans to make CBD treatments available through Medicaid during his campaign, framing it as an expansion of medical access for conditions like chronic pain and anxiety. But the spending bill's final text offers no pathway to reconcile that promise with federal restrictions on hemp-derived cannabinoids.

CBD products themselves don't contain significant THC levels—the compound that produces intoxication. Yet the hemp supply chain often involves plants and extracts that contain higher THC concentrations during processing. Industry analysts note that stricter enforcement of THC limits could disrupt CBD production even for non-intoxicating final products.

"The hemp industry has been operating in a gray area since the 2018 Farm Bill," said Jonathan Miller, general counsel for the U.S. Hemp Roundtable, in previous congressional testimony. "Clear rules are needed, but so is realistic implementation time."

What This Means for Manufacturers

Hemp businesses face immediate compliance questions. The 2018 Farm Bill legalized hemp with less than 0.3% delta-9 THC, but left regulatory details to the USDA and FDA. The resulting patchwork has allowed delta-8 THC and other hemp-derived intoxicants to flourish in a legal gray zone—products that some states have moved to restrict or ban outright.

Without the spending bill protections, federal agencies can proceed with enforcement actions against products exceeding THC thresholds. That puts manufacturers in a bind: reformulate products to comply with stricter interpretations, or risk federal action.

The CBD market alone generated $4.6 billion in sales in 2023, according to Hemp Industry Daily data. A significant portion involves products that touch THC-containing materials during cultivation or extraction, even if the final consumer product contains only trace amounts.

The Medicaid Question

Trump's Medicaid coverage proposal for CBD remains undefined in terms of policy mechanics. The Centers for Medicare & Medicaid Services would need to classify CBD as a covered treatment, a process requiring FDA approval for specific medical indications. Currently, only one CBD drug—Epidiolex, for rare seizure disorders—has FDA approval.

Expanding Medicaid coverage to other CBD applications would require either new FDA approvals or changes to how CMS evaluates coverage for supplements and alternative treatments. Policy experts suggest both paths face significant regulatory hurdles, now complicated further by the hemp THC enforcement picture.

What's Next

The spending bill moves to floor votes in both chambers this week. Hemp industry groups continue lobbying for standalone legislation that would provide clearer regulatory frameworks and implementation timelines. Several bills introduced in previous sessions aimed to address hemp-derived intoxicants, but none advanced to passage.

Meanwhile, the FDA has yet to issue comprehensive regulations for CBD in foods and supplements—a rulemaking process that began after the 2018 Farm Bill but remains incomplete. That vacuum has allowed state-by-state approaches to proliferate, creating a fragmented national market.

For patients and manufacturers awaiting clarity on CBD's medical future, the spending bill's final language offers little immediate relief. The path forward depends on whether the administration can reconcile its Medicaid expansion goals with federal hemp enforcement—a policy puzzle that remains unsolved.

---

This article is based on original reporting by mjbizdaily.com.